Febuxostat, which reduces production of uric acid, may slow renal function decline in patients with chronic kidney disease (CKD) and asymptomatic hyperuricemia, according to researchers. Patients treated with the uric acid-lowering drug were less likely to experience a greater than 10% decline in eGFR than placebo recipients.
A Study with 93 patients with CKD stages 3 and 4 and asymptomatic hyperuricemia to receive 40 mg of febuxostat (45 patients) or placebo (48 patients) once daily for 6 months. Patients were followed up for 6 months to evaluate changes in eGFR. The primary study outcome was the proportion of patients showing a greater than 10% decline in estimated glomerular filtration rate (eGFR) from baseline.